PM
Prosight Management Portfolio holdings
AUM
$580M
Turnover
39.22%
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+16.3%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$122M
AUM Growth
-$94.3M
(-44%)
Cap. Flow
-$101M
Cap. Flow
% of AUM
-82.94%
Top 10 Holdings %
Top 10 Hldgs %
59.86%
Holding
56
New
14
Increased
5
Reduced
18
Closed
19
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$6.12M |
| 2 |
Kezar Life Sciences
KZR
|
+$4.39M |
| 3 |
Cellectis
CLLS
|
+$3.41M |
| 4 |
Oscar Health
OSCR
|
+$3.35M |
| 5 |
Solid Biosciences
SLDB
|
+$2.36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Organogenesis Holdings
ORGO
|
+$27.2M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$25.8M |
| 3 |
Prothena Corp
PRTA
|
+$9.24M |
| 4 |
Baxter International
BAX
|
+$9.15M |
| 5 |
Cigna
CI
|
+$8.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.63% |
| 2 | Energy | 1.37% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Prothena Corp
PRTA
$430M
| $15.1M | 12.34% |
600,000
-491,202
| -45% | -$9.24M |
2020 Q3
2 quarters
|
|
2
Vertex Pharmaceuticals
VRTX
$126B
| $8.24M | 6.75% |
38,350
+9,450
| +33% | +$2.08M |
2020 Q4
1 quarter
|
|
3
Encompass Health
EHC
$12.5B
| $8.19M | 6.71% |
125,700
-17,975
| -13% | -$1.17M |
2020 Q1
4 quarters
|
|
|
ARNA
4
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $7.34M | 6.01% |
105,828
-39,872
| -27% | -$3.07M |
2018 Q1
12 quarters
|
|
5
Cue Biopharma
CUE
$135M
| $6.79M | 5.56% |
18,559
-11,660
| -39% | -$4.8M |
2019 Q4
5 quarters
|
|
6
Bristol-Myers Squibb
BMY
$121B
| $6.04M | 4.94% |
95,600
-73,400
| -43% | -$4.57M |
2020 Q2
3 quarters
|
|
|
ALBO
7
DELISTED
Albireo Pharma Inc
ALBO
| $6M | 4.92% |
170,352
-4,439
| -3% | -$164K |
2018 Q3
10 quarters
|
|
8
Aldeyra Therapeutics
ALDX
$47.7M
| $5.63M | 4.61% |
473,446
-435,042
| -48% | -$5.01M |
2018 Q4
9 quarters
|
|
|
9
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $5.12M | 4.19% |
+66,419
| New | +$6.12M |
2021 Q1
0 quarters
|
|
10
Aurinia Pharmaceuticals
AUPH
$2.21B
| $4.68M | 3.84% |
360,834
-147,881
| -29% | -$2.15M |
2020 Q2
3 quarters
|
|
|
11
DELISTED
Kezar Life Sciences
KZR
| $4.47M | 3.66% |
+75,031
| New | +$4.39M |
2021 Q1
0 quarters
|
|
12
MeiraGTx Holdings
MGTX
$904M
| $4.21M | 3.45% |
291,944
-89,175
| -23% | -$1.39M |
2019 Q3
6 quarters
|
|
|
ZGNX
13
DELISTED
Zogenix, Inc.
ZGNX
| $3.81M | 3.12% |
195,000
+45,478
| +30% | +$933K |
2020 Q1
4 quarters
|
|
14
Zimmer Biomet
ZBH
$17.5B
| $3.39M | 2.78% |
21,833
-14,733
| -40% | -$2.28M |
2018 Q3
10 quarters
|
|
15
ProQR Therapeutics
PRQR
$207M
| $2.98M | 2.44% |
450,165
+195,165
| +77% | +$997K |
2020 Q4
1 quarter
|
|
|
16
Oscar Health
OSCR
$10.6B
| $2.88M | 2.36% |
+107,086
| New | +$3.35M |
2021 Q1
0 quarters
|
|
|
17
Cellectis
CLLS
$113M
| $2.79M | 2.28% |
+137,900
| New | +$3.41M |
2021 Q1
0 quarters
|
|
18
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $2.45M | 2% |
85,000
-145,877
| -63% | -$3.75M |
2020 Q4
1 quarter
|
|
19
Medtronic
MDT
$121B
| $2.37M | 1.94% |
+20,088
| New | +$2.35M |
2021 Q1
0 quarters
|
|
20
UnitedHealth
UNH
$355B
| $2.23M | 1.83% |
+6,000
| New | +$2.08M |
2021 Q1
0 quarters
|
|
21
Tvardi Therapeutics
TVRD
$13.3M
| $2.17M | 1.78% |
2,778
-5,390
| -66% | -$3.69M |
2020 Q2
3 quarters
|
|
|
MTCR
22
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $1.89M | 1.55% |
304,485
-258,818
| -46% | -$2.29M |
2020 Q3
2 quarters
|
|
|
23
Solid Biosciences
SLDB
$585M
| $1.77M | 1.45% |
+21,340
| New | +$2.36M |
2021 Q1
0 quarters
|
|
|
LHCG
24
DELISTED
LHC Group LLC
LHCG
| $1.68M | 1.37% |
8,783
+6,037
| +220% | +$1.21M |
2020 Q4
1 quarter
|
|
|
AKU
25
DELISTED
Akumin Inc
AKU
| $1.59M | 1.3% |
429,061
+204,788
| +91% | +$690K |
2020 Q4
1 quarter
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q1 2021 Portfolio in Review
As of Q1 2021, Prosight Management held 56 positions worth $122M, down 44% from $216M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Prosight Management withdrew a net $101M in Q1 2021, closing 19 positions and reducing 18 holdings. Its most notable exit was Cigna, an estimated $8.62M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 88% a quarter earlier, followed by Energy and Technology.
Against the trend, Prosight Management opened a new position in Lakefront Biotherapeutics American Depositary Shares worth $5.12M.
- Prosight Management's largest Q1 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 66,419 shares worth $5.12M.
- Prosight Management added most to Vertex Pharmaceuticals in Q1 2021, an estimated $2.08M increase.
- Prosight Management's biggest Q1 2021 reduction was Organogenesis Holdings, cutting an estimated $27.2M.
- Prosight Management fully exited Cigna in Q1 2021, selling an estimated $8.62M.
- Prosight Management's ten largest holdings make up 60% of its $122M portfolio in Q1 2021.
- Prosight Management opened 14 new positions and closed 19 in Q1 2021.
- Prosight Management's portfolio value fell 44% quarter-over-quarter to $122M.
Based on Prosight Management's 13F filing for Q1 2021, filed 14 May 2021.